Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butabarbital is a barbiturate drug with sedative and hypnotic properties, primarily used for the short-term treatment of insomnia and to alleviate anxiety, including pre-surgical anxiety. It functions as a non-selective central nervous system depressant by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor, which prolongs chloride ion channel opening and leads to neuronal hyperpolarization. Additionally, it directly inhibits AMPA-type glutamate receptors and neuronal acetylcholine receptors, thereby suppressing excitatory neurotransmission. Butabarbital has a relatively fast onset and intermediate duration of action, and it is classified as a Schedule III controlled substance due to its potential for abuse and dependence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Butabarbital.